Clinical Rheumatology

, Volume 38, Issue 3, pp 761–768 | Cite as

Evaluation of treatment adherence in patients with Behçet’s disease: its relation to disease manifestations, patients’ beliefs about medications, and quality of life

  • Hania S Zayed
  • Basma M MedhatEmail author
  • Esraa M Seif
Original Article



Despite its importance, adherence to treatment has not been sufficiently studied in Behçet’s disease (BD). The aim of this study was to evaluate medication adherence in BD using the Compliance Questionnaire of Rheumatology (CQR) and factors potentially affecting it.


This cross-sectional study included 67 consecutive BD patients including 57 (85%) males with a mean age of 35.1 ± 9.27 years and mean disease duration of 129 ± 91 months. The cumulative clinical manifestations, the Behçet’s Disease Current Activity Form (BDCAF) score, and the Vasculitis Damage Index (VDI) were recorded. The CQR, Socioeconomic Status Questionnaire for Health Research in Egypt (SES), the Beliefs about Medication Questionnaire (BMQ), and the Short Form 36 (SF-36) quality of life assessment questionnaire were administered to the patients. Linear regression analysis was done to determine independent predictors of CQR.


The mean BDCAF score was 3.27 ± 3.54 and the VDI was 3.36 ± 2.21. The mean CQR score was 69.2 ± 11.79. The CQR score varied significantly among different health sources (p = 0.02), with no relationship detected with other sociodemographic characteristics, nor with clinical characteristics or the SF-36. Among the investigated medications’ complexities, severity of side effects showed significantly different CQR scores (p = 0.004), and a weak positive correlation between medications’ numbers and the CQR was detected. Predictors for higher CQR scores included the necessity beliefs score of the BMQ (β = 1.1, p < 0.001); whereas, predictors for lower CQR scores were the harm and concern BMQ subscales ((β = − 1.5, p = 0.004) and (β = − 0.72, p = 0.032), respectively).


Beliefs about medications were the only predictor for adherence in our cohort.


Adherence Behçet’s disease Beliefs about medications Compliance Quality of life 


Compliance with ethical standards

The study was approved by the local Ethics Committee, according to the provisions of the World Medical Association Declaration of Helsinki.




  1. 1.
    Behcet H (1937) Uber rezidivierende, aphthose durch ein Virus verursachte Geschwure am Mund, am Auge und an den Genitalian. Dermatol Wochenschr 105:1152–1157Google Scholar
  2. 2.
    Alpsoy E (2016) Behçet’s disease: a comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol 43(6):620–632. CrossRefPubMedGoogle Scholar
  3. 3.
    Hatemi G, Merkel PA, Hamuryudan V, Boers M, Direskeneli H, Aydin SZ, Yazici H (2014) Outcome measures used in clinical trials for Behçet syndrome: a systematic review. J Rheumatol 41(3):599–612. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health J 11(1):44–47. CrossRefGoogle Scholar
  5. 5.
    Vangeli E, Bakhshi S, Baker A, Fisher A, Bucknor D, Mrowietz U, Östör AJ, Peyrin-Biroulet L, Lacerda AP, Weinman J (2015) A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther 32(11):983–1028. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Voshaar M, Vriezekolk J, van Dulmen S, van den Bemt BJ, van de Laar M (2016) Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study. BMC Musculoskelet. Disord 17(1):442. CrossRefGoogle Scholar
  7. 7.
    Khabbazi A, Karkon Shayan F, Ghojazadeh M, Kavandi H, Hajialiloo M, Esalat Manesh K, Kolahi S (2017) Adherence to treatment in patients with Behcet’s disease. Int J Rheum Dis.
  8. 8.
    de Achaval S, Suarez-Almazor ME (2010) Improving treatment adherence in patients with rheumatologic disease. J Musculoskelet Med 27(10):1691476PubMedPubMedCentralGoogle Scholar
  9. 9.
    Kim D, Choi JY, Cho SK, Choi CB, Bang SY, Cha HS, Choe JY, Chung WT, Hong SJ, Kim TH, Kim TJ (2018) Prevalence and associated factors for non-adherence in patients with rheumatoid arthritis. J Rheum Dis 25(1):47–57. CrossRefGoogle Scholar
  10. 10.
    Arturi P, Schneeberger EE, Sommerfleck F, Buschiazzo E, Ledesma C, Cocco JA, Citera G (2013) Adherence to treatment in patients with ankylosing spondylitis. Clin Rheumatol 32(7):1007–1015. CrossRefPubMedGoogle Scholar
  11. 11.
    Ragab OM, Zayed HS, Abdelaleem EA, Girgis AE (2017) Effect of early treatment with disease-modifying anti-rheumatic drugs and treatment adherence on disease outcome in rheumatoid arthritis patients. Egypt Rheumatologist 39(2):69–74. CrossRefGoogle Scholar
  12. 12.
    Prados-Moreno S, Sabio JM, Pérez-Mármol JM, Navarrete-Navarrete N, Peralta-Ramírez MI (2017) Adherence to treatment in patients with systemic lupus erythematosus. Med Clín (English Edition) 150:8–15. CrossRefGoogle Scholar
  13. 13.
    Prudente LR, Diniz JS, Ferreira TXAM, Lima DM, Silva NA, Saraiva G, Silveira EA, Dewulf NLS, Amaral RG (2016) Medication adherence in patients in treatment for rheumatoid arthritis and systemic lupus erythematosus in a university hospital in Brazil. Patient Prefer Adherence 10:863–870. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Mehat P, Atiquzzaman M, Esdaile JM, AviÑa-Zubieta A, De Vera MA (2017) Medication nonadherence in systemic lupus erythematosus: a systematic review. Arthritis Care Res 69(11):1706–1713. CrossRefGoogle Scholar
  15. 15.
    Zhang L, Lu GH, Ye S, Wu B, Shen Y, Li T (2017) Treatment adherence and disease burden of individuals with rheumatic diseases admitted as outpatients to a large rheumatology center in Shanghai, China. Patient Preference Adherence 11:1591–1601. CrossRefPubMedGoogle Scholar
  16. 16.
    Bruce IN, Gladman DD, Urowitz MB (2000) Factors associated with refractory renal disease in patients with systemic lupus erythematosus: the role of patient nonadherence. Arthritis Care Res 13:406–408.<406::AID-ART11>3.0.CO;2-2 CrossRefPubMedGoogle Scholar
  17. 17.
    Julian LJ, Yelin E, Yazdany J, Panopalis P, Trupin L, Criswell LA, Katz P (2009) Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Rheum 61:240–246. CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Wan GJ, Kozma CM, Slaton TL, Olson WH, Feagan BG (2014) Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy. J Med Econ 17(6):384–393. CrossRefPubMedGoogle Scholar
  19. 19.
    Cinar M, Cinar FI, Acikel C, Yilmaz S, Çakar M, Horne R, Simsek I (2016) Reliability and validity of the Turkish translation of the beliefs about medicines questionnaire (BMQ-T) in patients with Behçet’s disease. Clin Exp Rheumatol 34(6):S46–S51PubMedGoogle Scholar
  20. 20.
    Cinar M, Cinar FI, Yilmaz S, Acikel C, Cakar M, Simsek I (2016) SAT0359 evaluation of medication compliance in Behcet’s disease. Ann Rheum Dis 75:797. CrossRefGoogle Scholar
  21. 21.
    Mumcu G, Alibaz-Öner F, Öner SY, Özen G, Atagündüz P, İnanç N, Köksal L, Ergun T, Direskeneli H (2017) Oral ulcer activity in Behcet’s disease: poor medication adherence is an underestimated risk factor. Eur J Rheumatol 4(2):109–112. CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    de Klerk E, van der Heijde D, van der Tempel H, van der Linden S (1999) Development of a questionnaire to investigate patient compliance with antirheumatic drug therapy. J Rheumatol 26(12):2635–2641PubMedGoogle Scholar
  23. 23.
    van den Bemt BJF, Zwikker HE, van den Ende CHM (2012) Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol 8(4):337–351CrossRefPubMedGoogle Scholar
  24. 24.
    Davatchi F, Assaad-Khalil S, Calamia KT, Crook JE, Sadeghi-Abdollahi B, Schirmer M, Tzellos T, Zouboulis CC, Akhlagi M, Al-Dalaan A, Alekberova ZS et al (2014) International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD). The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28(3):338–347. CrossRefGoogle Scholar
  25. 25.
    El-Gilany A, El-Wehady A, El-Wasify M (2012) Updating and validation of the socioeconomic status scale for health research in Egypt/Mise à jour et validation d’une échelle du statut socioéconomique pour la recherche en santé en Égypte. East Mediterr Health J 18(9):962–968CrossRefPubMedGoogle Scholar
  26. 26.
    Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ (1999) Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatol 38(8):728–733. CrossRefGoogle Scholar
  27. 27.
    Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, Adu D (1997) Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 40(2):371–380. CrossRefPubMedGoogle Scholar
  28. 28.
    Davydov VF (1980) Types of drug side effects and their classification. Farmakol Toksikol 43(6):652–661PubMedGoogle Scholar
  29. 29.
    Hays RD, Sherbourne CD, Mazel RM (1993) The RAND 36-Item Health Survey 1.0. Health Econ 2(3):217–227. CrossRefPubMedGoogle Scholar
  30. 30.
    Horne R (1999) Patients’ beliefs about treatment: the hidden determinant of treatment outcome? J Psychosom Res 47(6):491–495. CrossRefPubMedGoogle Scholar
  31. 31.
    Alsous M, Alhalaiqa F, Abu Farha R, Abdel Jalil M, McElnay J, Horne R (2017) Reliability and validity of Arabic translation of Medication Adherence Report Scale (MARS) and Beliefs about Medication Questionnaire (BMQ)-specific for use in children and their parents. PloS One 12(2):e0171863. CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Gottlieb H (2000) Medication nonadherence: finding solutions to a costly medical problem CME. Drug Benefit Trends 12(6):57–62Google Scholar
  33. 33.
    Jimmy B, Jose J (2011) Patient medication adherence: measures in daily practice. Oman Med J 26(3):155–159. CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Joplin S, van der Zwan R, Joshua F, Wong PK (2015) Medication adherence in patients with rheumatoid arthritis: the effect of patient education, health literacy, and musculoskeletal ultrasound. Biomed Res Int 2015:110. CrossRefGoogle Scholar
  35. 35.
    de Klerk E, van der Heijde D, Landewé R, van der Tempel H, van der Linden S (2003) The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. J Rheumatol 30(11):2469–2475PubMedGoogle Scholar
  36. 36.
    Treharne G, Lyons A, Kitas G (2004) Medication adherence in rheumatoid arthritis: effects of psychosocial factors. Psychology, health & medicine 9(3):337–349. CrossRefGoogle Scholar
  37. 37.
    van den Bemt BJF, van den Hoogen FHJ, Benraad B, Hekster YA, van Riel PLCM, van Lankveld W (2009) Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J Rheumatol 36(10):2164–2170. CrossRefPubMedGoogle Scholar
  38. 38.
    Hromadkova L, Soukup T, Vlcek J (2015) Quality of life and drug compliance: their interrelationship in rheumatic patients. J Eval Clin Pract 21(5):919–924. CrossRefPubMedGoogle Scholar
  39. 39.
    Morgan C, McBeth J, Cordingley L, Watson K, Hyrich KL, Symmons DP, Bruce IN (2015) The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. Rheumatology 54(10):1780–1791. CrossRefPubMedGoogle Scholar
  40. 40.
    de Thurah A, Nørgaard M, Harder I, Stengaard-Pedersen K (2010) Compliance with methotrexate treatment in patients with rheumatoid arthritis: influence of patients’ beliefs about the medicine. A prospective cohort study. Rheumatol Int 30(11):1441–1448. CrossRefPubMedGoogle Scholar
  41. 41.
    Kuipers JG, Koller M, Zeman F, Mueller K, Rueffer JU (2017) THU0115 disability (HAQ) and quality of life (SF-12) as related to adherence and health literacy in patients with rheumatoid arthritis. Ann Rheum Dis 76:244. CrossRefGoogle Scholar
  42. 42.
    Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23(8):1296–1310. CrossRefPubMedGoogle Scholar
  43. 43.
    Müller R, Kallikorm R, Põlluste K, Lember M (2012) Compliance with treatment of rheumatoid arthritis. Rheumatol Int 32(10):3131–3135. CrossRefPubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  1. 1.Rheumatology and Rehabilitation department, Faculty of MedicineCairo UniversityCairoEgypt

Personalised recommendations